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Antibody-targeted liposomal anticancer drugs combine the specificity of antibodies with large payloads of entrapped drugs. We previously
showed that liposomal doxorubicin (DXR) targeted via anti-CD19 monoclonal antibodies (mAb) or their Fab' fragments against the B-cell antigen
CD19 led to improved therapeutic effects in murine B-cell lymphoma models relative to non-targeted liposomal DXR. We now are examining the
use of anti-CD19 single chain fragments of the antibody variable region (scFv) as a targeting moiety, to test the hypothesis that scFv have
advantages over full-sized mAb or Fab' fragments. We expressed two different anti-CD19 scFv constructs, HD37-C and HD37-CCH in E. coli,
and purified the scFvs using two different methods. The HD37-CCH construct was selected for coupling studies due to its relative stability and
activity in comparison to HD37-C. When coupled to liposomes, the HD37-CCH scFv showed increased binding in vitro to CD19-positive Raji
cells, compared to non-targeted liposomes. Cytotoxicity data showed that HD37-CCH scFv-targeted liposomes loaded with DXR were more
cytotoxic than non-targeted liposomal DXR. Our results suggest that anti-CD19 scFv constructs should be explored further for their potential in
treating B-lymphoid leukemias and lymphomas.
© 2006 Elsevier B.V. All rights reserved.Keywords: Anti-CD19; scFv; Liposome; Doxorubicin; B-lymphoid cell; Immunoliposome1. Introduction
The use of antibodies and antibody fragments as cancer
therapeutics have flourished in recent years and led to the
clinical approval of several monoclonal antibodies, including
Rituxan® (rituximab) and Herceptin® (trastuzumab) [1,2].
Currently, more than 150 mAbs are in clinical trials worldwide
[3]. Immuno-conjugates, where mAbs are covalently linked to a
few molecules of drugs, toxins or radioisotopes, have also been
successfully commercialized, e.g., Zevalin® (ibritumomab
tiuxetan), Bexxar (131I-tositumomab), and Mylotarg® (gemtu-
zumab ozogamicin) [4–6]. Additive or synergistic effects have
been demonstrated in patients when combinations of signaling
antibodies such as rituximab and conventional chemotherapeu-
tic drugs are administered [7,8].
Although mAbs can be highly selective for their targets, their
properties are not ideal for continued administration in patients⁎ Corresponding author. Fax: +1 780 492 8078.
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containing foreign (e.g., mouse) regions [9]. Antibody frag-
ments, such as Fab' fragments (∼55 kDa) and single chain
fragments of the variable region (∼35 kDa) lack the Fc
antibody fragment, and thus the dominant immunogenic
determinants. Fab' and scFv fragments can be selected by
phage display and are more easily engineered than mAbs to
control properties such as affinity or internalization capabilities
[10]. They can be produced by a variety of methods including
bacterial and algal fermentation, which should decrease their
production costs [11]. Many laboratories are currently investi-
gating the use of these small fragments for the treatment of
cancers [12–17].
Liposomes are phospholipid bilayer spheres that can
encapsulate drugs in their aqueous interior. The grafting of
polyethylene glycol (PEG) to the surface of liposomes (termed
Stealth® liposomes) serves two purposes: the polymer terminus
is a convenient location for the coupling of targeting ligands
such as mAbs and derived fragments, and these liposomes have
circulation half-lives of several hours, which allows sufficient
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[13,15,18,19]. Several liposomal drugs are currently on the
market, including Caelyx/Doxil® (a Stealth® liposomal for-
mulation of the anticancer drug doxorubicin (DXR), which is
approved for AIDS-related Kaposi's sarcoma, refractory
ovarian and metastatic breast cancers) [20]. Currently no
ligand-targeted liposomes are in the clinic, but extensive
preclinical research activity is taking place in this area. The
concept is similar to that of antibody-drug conjugates, with the
advantage that targeted liposomes can deliver a far greater
payload of drug per antibody, i.e., several hundred drug
molecules per antibody, relative to less than 10 drug molecules
per antibody for the antibody–drug conjugates. This can result
in increased therapeutic effect for fewer antibodies, leading to
reduced antibody-associated side effects and reduced expense
[20–23].
We have had a long-standing interest in disease targets that
are readily accessible from the vasculature, including B and T
cell haematological malignancies and the vasculature of solid
tumors. Non-Hodgkin's lymphoma, the most common B-cell
malignancy, is the 5th most common cause of new cases of
cancer in North America and accounts for approximately 4 to
5% of new cases of cancer every year [24,25]. B-cell
malignancies generally respond well to initial chemotherapy,
especially the combination of Rituxan® plus CHOP (cyclopho-
samide, doxorubicin, vincristine and prednisone) [8,26,27].
Unfortunately, a substantial percentage of patients who respond
to initial therapy will relapse. This is thought to result from the
incomplete eradication of residual malignant B-lymphoid cells
and/or their progenitors, and justifies the search for therapies
that can eradicate these cells. The CD19, CD20 and CD22
antigens are expressed on a high percentage of malignant B-
lymphoid cells in lymphoma patients [25,28,29]. Since these
antigens are found primarily on mature B cells and not on their
precursor cells, they are good targets for directing therapeutics
against malignant B-lymphoid cells.
We had previously shown that anti-CD19-targeted liposomal
DXR led to improved therapeutic effects in murine models of
human B lymphoma (Namalwa) relative to free DXR or non-
targeted liposomal DXR [16,18,30,31]. We are now exploring
the potential advantages of using scFv fragments, in relation to
mAb and Fab', for targeting liposomes to B-cell malignancies.
In the current study, two constructs of anti-CD19 scFv were
tested separately for ease of production from E. coli fermenta-
tion and for ease of purification, storage and stability. The most
suitable candidate was selected and conjugated to liposomes.
Cell binding and cytotoxicity of the anti-CD19 scFv immuno-
liposomes were compared to non-targeted liposomes.
2. Materials and methods
2.1. Materials
Hydrogenated soy phosphatidylcholine (HSPC) and methoxypoly(ethylene
glycol) (MW 2000), covalently linked to distearoylphosphatidylethanolamine
(mPEG2000-DSPE), were generous gifts from ALZA Corporation, Inc.
(Mountain View, CA). Cholesterol (Chol) and 1-oleoyl-2-[6-[(7-nitro-2-1,3-
benzoxadiazol-4-yl)amino]hexanoyl]-sn-glycero-3-phosphoethanolamine(NBD-PE) were purchased from Avanti Polar Lipids (Alabaster, AL).
Maleimide-derivatized PEG3400-DSPE (Mal-PEG3400-DSPE) was custom
synthesized by Nektar Therapeutics (Huntsville, AL). Chol-[1,2-3H-(N)]
hexadecyl ether ([3H]CHE, 1.48-2.22 TBq/mmol) and 125I-NaI, 185 MBq
were purchased from Perkin Elmer Life Sciences (Woodbridge, ON). Bio-Rad
Protein Assay Reagent was purchased from Bio-Rad Laboratories (Mississauga,
ON). β-mercaptoethanol (β-ME), 2-iminothiolane (Traut's Reagent), L-arginine
(L-Arg), Protein L Agarose columns, goat anti-mouse fluorescein isothiocyanate
(GAM-FITC) conjugate and RPMI 1640 media were obtained from Sigma
Chemical Co. (St. Louis, MO). 1,4-dithiothreitol (DTT) was purchased from
Fisher Scientific (Nepean, ON). Nuclepore polycarbonate membranes (pore
sizes, 0.4, 0.2, 0.1, and 0.08 μm) were purchased from Northern Lipids
(Vancouver, BC). Sephadex G-50, Sephadex G-25, Sepharose CL-4B and
Aqueous Counting Scintillant (ACS) were purchased from Amersham
Biosciences (Baie d'Urfe, PQ). Nickel-nitrilotriacetic acid (Ni-NTA) column
and murine anti-polyhistidine (anti-His) mAb were purchased from Qiagen
(Qiagen, Hilden, Germany). Penicillin-streptomycin-L-glutamine (P/S/G), and
fetal bovine serum were obtained from Invitrogen (Burlington, ON). Bacto
Tryptone, Bacto Yeast Extract and Bacto Agar were from BD (Sparks, MD). All
other chemicals were of the highest grade possible.
2.2. Cell lines and antibodies
The human Burkitt's lymphoma cell lines (Namalwa and Raji) and the
human T-lymphoma cell line (Molt 4) were purchased from the American Type
Culture Collection. The cells were cultured in suspension in RPMI 1640 media
supplemented with 10% (V/V) fetal bovine serum, and 1% (V/V) P/S/G in a
humidified 37 °C incubator with a 5% CO2 atmosphere. Cell surface expression
of CD19 was determined using single-color flow cytometry. Briefly, 1×106 cells
were stained with a CD19 mAb, followed by a secondary antibody, GAM-FITC.
Cell-associated fluorescence was analyzed on a Becton Dickinson FACScan
using Lysis II software (Becton Dickinson, San Jose, CA).
The murine anti-CD19 mAbs, FMC63 mAb (IgG2a) and HD37 mAb (IgG1),
were produced from the FMC63 [32] and HD37 hybridomas [33], obtained from
Dr. H. Zola (Children's Health Research Institute, Adelaide, Australia) and Dr.
B. Doerken (Charité, University Medicine, Berlin, Germany) via Dr. E. Vitetta
(University of Texas Southwestern Medical Center, Dallas, TX), respectively.
Two scFv constructs were used. The scFvs from the HD37 mAb were courtesy
of Dr. S. Kipriyanov from Affimed Therapeutics AG, Heidelberg, Germany
[34]. HD37-c-myc-Cys-His5 scFv (HD37-CCH) contains the c-myc and His5
tags for identification and purification, and a cysteine residue for coupling to
liposomes. HD37-Cys (HD37-C) scFv, which contains a terminal cysteinyl
residue for coupling to liposomes, was prepared by removing the tags from a
HD37-c-myc-His6-Cys (HD37-CHC) construct as described below.
The PCR method was used to amplify the HD37-C scFv from HD37-c-myc-
His6-Cys (HD37-CHC) in the pSKK vector [35]. Gene specific primers (forward
primer, P1, 5' CTG CTG GCA GCT CAG CCG GCC ATG GCG CAG 3'; and
Backward primer, P2, 5' TTA GCA CAG GCC TCTAGATTA GCA GGATCC
AGC ATC AGC CCG TTT GAT TTC CAG CTT GGT GCC 3') were designed
with suitable restriction enzyme sites (NcoI in P1 and XbaI in P2) in both primers,
respectively, and a Cys codon was added before the stop codon in the P2 primer.
PCR products were analysed by 1% agarose/TAE (40 mM Tris, 20 mM acetic
acid, 1 mM EDTA) gel electrophoresis and amplified products were purified using
a QIAquick gel extraction kit (Qiagen, Germany). Both the PCR product and the
pSKK vector were digested with NcoI+XbaI endonucleases, gel purified and
ligated overnight at 14 °C. The ligation mixture was transformed into E. coli
Top10F electrocompetent cells (Invitrogen, Burlington, ON) by electroporation.
Recombinant clones were screened by restriction digestion fragment analysis of
the plasmid DNA, digested with NcoI and XbaI endonucleases. Digested products
were analyzed by 1% agarose/TAE gel electrophoresis and the correct size insert
was confirmed by restriction digestion fragment mapping.
2.3. Expression of scFv clones
For HD37-C, a recombinant plasmid carrying the scFv gene was used to
transform E. coli RV308 by a heat shock method [36]. E. coli RV308
transformants were propagated in 5 mL of 2YT (1.6% tryptone, 1% yeast extract
and 0.5% NaCl, pH 7.5), containing 100 μg/mL of ampicillin, and were
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(OD600) of approximately 0.8 was reached. The bacterial culture was induced
with 1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG) and allowed to grow
for 16 h at 22 °C. Bacteria were then harvested by centrifugation at 5000×g for
10 min at 4 °C and a total cell lysate was prepared by addition of sample buffer
to the pellet and heating at 95 °C for 5 min [36]. Total cell protein was analyzed
by SDS-PAGE using 10% polyacrylamide gels performed according to Laemmli
[37] with a Mini Protean II apparatus (Bio-Rad). The protein gel was stained
with 0.25% Coomassie Brilliant Blue R-250.
2.4. Western blot analysis of expressed scFv constructs
Total cell protein was separated on SDS-PAGE using a 10% Tris SDS-PAGE
gel and transferred to a Hybond ECL nitrocellulose membrane [38] using a
Trans-Blot apparatus (Bio-Rad, Mississauga, ON) following manufacturer's
instructions. The ECL membrane was blocked with 5% skim milk in 0.1%
Tween 20 in phosphate buffer saline, pH 7.3 (PBST) for 1 h. The membrane was
washed with PBSTand incubated with Protein-L horse-radish peroxidase (HRP)
and anti-His mAb for 1 h. After incubation, the membrane was washed with
PBST and incubated with goat anti-mouse HRP (GAM-HRP, Upstate, Lake
Placid, NY). In some cases the membranes were reacted with Protein-L-HRP for
1 h. Finally, the membrane was washed 4 times with PBST and enhanced
chemiluminescent-based detection was done according to the manufacturer's
protocol (ECLWestern blot analysis system, Amersham Biosciences, PQ).
2.5. Expression and extraction of HD37-C and HD37-CCH from the
periplasmic space and inclusion bodies
The scFv constructs were expressed using the pSKK vector in RV 308 E.
coli in shaker cultures as described above. Expression of the scFvs was induced
with 0.2 mM of IPTG at 22 °C when OD600 reached 0.8. Cells were harvested by
centrifugation after 16 h of induction.
For extraction of HD37-C from the periplasmic space of E. coli, cells were
incubated with the periplasmic extraction buffer (100 mM Tris HCl, 20% W/V
sucrose, 1 mMEDTA, pH 8.0) for 1 h on ice. Cells were then centrifuged and the
extracted scFv fragments were collected in the supernatant as periplasmic
extract. The HD37-C scFv was purified from the periplasmic extract using a
Protein L agarose column as previously described [35]. Briefly, the periplasmic
extract was extensively dialyzed in phosphate buffered saline (PBS) at pH 7.4
before loading onto the column at 20 mL/h, using a peristaltic pump. The
column was washed with PBS (pH 7.4) to remove non-specifically bound
proteins. The scFv was eluted with elution buffer (100 mM glycine, pH 2.0) and
immediately neutralized with addition of 1 M Tris at pH 9.0 to achieve a final pH
of 7.4. Fractions were analyzed by SDS-PAGE and Western blot.
Alternatively, HD37-C was isolated from inclusion bodies and was purified
as previously described with slight modification [35]. Cell pellets from
periplasmic extraction were resuspended in Lysis Buffer 1 (50 mM Tris,
200 mM NaCl, 1 mM EDTA, pH 8.0) and lysed by either French Press or
sonication. The cells were then centrifuged at 10,000×g at 4 °C and the inclusion
bodies were collected as pellets. The inclusion bodies were resuspended and
incubated in 0.1% Triton X-100 for 0.5 h at room temperature and were then
centrifuged at 10,000×g at 4 °C. The inclusion bodies were washed with Lysis
Buffer 1 and resuspended in Lysis Buffer 2 (100 mM Tris, 200 mM NaCl, 1 mM
EDTA, pH 8.3). A previously described step-wise dialysis method, with
modification, was used for refolding the denatured HD37-C [39]. Inclusion
bodies were solubilized in Lysis Buffer 2 containing 6 M guanidine
hydrochloride (Gu HCl) and centrifuged at 10,000×g at 4 °C. Soluble protein
was collected in the supernatant and before dialysis the protein concentration
was adjusted to 100 μg/mL. Dialysis was conducted with sequential daily
decreases of Gu HCl (6, 3, 2, 1, 0.5, 0 M). At the 1 M and 0.5 M Gu HCl stages,
400 mM of L-arginine and 375 μM of oxidized glutathione (GSSG) were added
to assist the proper formation of disulfide bonds.
The procedure for extracting HD37-CCH from the periplasmic space was the
same as for HD37-C. After extraction, the periplasmic extract, containing the
HD37-CCH scFv, was extensively dialyzed in NI-NTADialysis Buffer (1MNaCl,
50 mM Tris HCl and 40 mM imidazole, pH 7.0). The dialyzed extract was then
incubated overnight at 4 °Cwith Ni-NTA at a 50:1 (V:V) ratio, with gentle rocking.
After the incubation, the Ni-NTA was packed into a column and washed withwashing buffers (1MNaCl, 50mMTris HCl, and 50 or 80mM imidazole, pH 7.0).
The HD37-CCH was then eluted with elution buffer (1 M NaCl, 50 mM Tris HCl
and 300 mM imidazole, pH 7.0). Elution fractions were analyzed on SDS-PAGE
gels and scFv-containing fractions were extensively dialyzed in PBS.
2.6. Preparation of liposomes
Non-targeted Stealth® liposomes (SL) were composed of HSPC:CHOL:
mPEG2000-DSPE at a 2:1:0.10 phospholipid molar ratios. Stealth® immunolipo-
somes (SIL) were composed of HSPC:CHOL:mPEG2000-DSPE:Mal-PEG3400-
DSPE at a molar ratio to HSPC of 2:1:0.08:0.02. [3H]CHE was added as a non-
exchangeable, non-metabolized lipid tracer [40,41]. Liposomes were prepared
as previously described [30]. Briefly, the lipid film was dried by rotovaporation
for 1 h and then placed in a high vacuum overnight. The lipid films were
hydrated at a concentration of 10–30 mM phospholipid (PL) with PBS (pH 8.0).
Hydrated liposomes were extruded at 65 °C through a series of Nuclepore
polycarbonate filters, with pore sizes from 0.4 μm to 0.08 μm, resulting in an
average final diameter in the range of 100±20 nm. The sizes of liposomes were
determined using dynamic light scattering (Brookhaven BI-90 Particle Sizer,
Holtsville, NY).
2.7. Preparation of immunoliposomes
HD37-C and HD37-CCH scFv fragments were coupled to liposomes
containing Mal-PEG-DSPE at a 1:500 scFv:HSPC molar ratio, as previously
described, with slight modifications [42]. The scFv fragments were reduced for 1 h
at room temperature with 14 mM β-ME and with 5 mM DTT for HD37-C and
HD37-CCH, respectively. 125I-labeled scFvs were used as tracers. Unreacted
reducing agents were removed from samples by Sephadex G-25 columns. ScFv
fragments were quickly combined with liposomes containing Mal-PEG3400-DSPE
and were allowed to incubate overnight at room temperature with stirring.
HD37 and FMC63 mAbs were thiolated with Traut's reagent at a ratio of
Traut's:IgG of 20:1 (mol/mol) in degassed HBS (pH 8.0) for 1 h. After
thiolation, unreacted Traut's reagent was removed from the sample via
Sephadex G-50 columns equilibrated with degassed HBS (pH 7.4). 125I-labeled
HD37 and FMC63 mAbs were used as tracers. Immediately after the column,
the thiolated antibody was added to liposomes at 1:1000 mAb:HSPC molar ratio
and incubated overnight at room temperature with stirring. Unconjugated
antibody and antibody-free liposomes were removed by chromatography on
Sepharose CL-4B columns in PBS, pH 8.0.
2.8. Flow cytometry studies
Fluorescence-activated cell sorting (FACS) experiments were conducted to
determine the binding of HD37-CCH scFvs to Raji cells. Briefly, 1×106 cells in
the exponential growth phase were seeded in sterile tubes. Cells were incubated
with scFvs for 1 h at 4 °C, and then washed with cold PBS. Binding of scFvs was
detected in a Becton Dickinson FACScan (BD Biosciences, Mississauga, ON)
after labeling with murine anti-His mAb followed by GAM-FITC. The binding
of scFvs to Raji cells was indicated by rightward shifts in the fluorescence peak.
Experiments to determine equilibrium dissociation constants (KD) were
performed as described with slight modifications [43]. Briefly, 2×105 Raji cells
were incubated with various concentrations of HD37 mAb or HD37-CCH in
PBS supplemented with 10% FBS (PBS/FBS) at a final volume of 1 mL for 3 h
at 4 °C. Cells were then washed twice with PBS/FBS. For HD37-CCH, cells
were then incubated with 20 μL of murine anti-His mAb (200 ng/mL) in PBS/
FBS for 1 h at 4 °C and then washed twice with PBS/FBS. Cells were then
incubated with 20 μL of a 1/50 dilution of GAM-FITC in PBS/FBS for 30 min at
4 °C. Cells were washed twice with PBS/FBS and resuspended in 0.5 mL of 4%
formaldehyde in PBS. Fluorescence was measured in a Becton Dickinson
FACScan and were normalized using the SPHERO™ FITC Calibration Particle
Kit (Spherotech, Libertyville, IL).
2.9. In vitro cellular binding studies using tritium-labeled liposomes
Cellular binding studies were performed as previously described [31]. The
association with B-lymphoid cells was determined for targeted and non-targeted
Fig. 1. Flow cytometry analysis. (A) 1×106 Namalwa cells treated with 10 μg of
either FMC63 mAb or HD37 mAb. Black: Control (no treatment), Grey:
FMC63 mAb, Black Solid: HD37 mAb. (B) Binding of periplasmic extracted
HD37-CCH with Raji cells. Black: control (no treatment); Black, solid: HD37-
CCH. Fluorescence shift to the right indicates binding to cells.
Fig. 2. SDS-PAGE and Western blot Analysis of HD37-C scFv fragments. (A)
SDS-PAGE gel of total cell lysates of bacteria expressing HD37-C. (C) Western
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seeded in sterile tubes. Cells were incubated with various formulations of
liposomes (SL, SIL[HD37-C], SIL[HD37-CCH], SIL[HD37 mAb] and SIL
[FMC63 mAb]) for 1 h at 37 °C, at PL concentrations ranging from 0.1 to
3.2 mM. Cells were then washed 3 times with cold PBS, and the amount of [3H]
CHE counts associated with cells was determined by scintillation counting
(Beckman LS-6800 Scintillation Counter, Beckman Coulter Canada, Inc.,
Mississauga, ON). Data were presented as nmol PL associated with 1×106 cells.
Specific binding was calculated by subtracting cell-associated radioactivity
counts of SL from SIL.
2.10. In vitro cytotoxicity studies
Cytotoxicity studies employed the MTT tetrazolium assay as previously
described [18]. Briefly, 8×105 Raji cells or 5×105 Molt 4 cells were incubated
with DXR-loaded SIL[HD37-CCH] (SIL-DXR[HD37-CCH]); SL-DXR; a
mixture of unconjugated HD37-CCH and SL-DXR (HD37-CCH+SL-DXR);
free HD37-CCH or free DXR for 1 h at 37 °C. Cells were then thoroughly
washed and were allowed to grow for another 48 h in full media. Treated cells
were compared to untreated cells to calculate percent of viable cells. In these
experiments, the commercially available liposomal DXR, Caelyx®, was used as
the non-targeted SL-DXR.blot of total cell lysates probed with murine anti-His mAb and then GAM-HRP
(A and C) Lane M, molecular weight marker; Lanes 1–6, representative samples
of induced RV308 clones expressing HD37-C; Lane 7, HD37-C-expressing
RV308 clone without induction; Lane 8, positive control (HD37-CHC
containing cell lysate). (B) Western blot of total cell lysates probed with Protein
L-HRP. Lane M, molecular weight marker; Lanes 1–6 representative samples of
induced RV308 clones expressing HD37-C; Lane 7, HD37-C-expressing RV308
clone without induction; Lanes 8 and 9, positive control (HD37-CHC containing
cell lysate) loaded at low and high concentrations, respectively.3. Results
Using FACS, we demonstrated that both parental full-length
CD19 mAbs, FMC63 and HD37, bound to the B-lymphoid cell
lines Namalwa and Raji (Fig. 1A). As well, the scFv fragment,
HD37-CCH, extracted from the periplasmic space also bound toRaji cells (Fig 1B). Using a Lineweaver–Burk analysis, the KD
of FMC63 mAb was found to be 1.1×10−9 M (not shown). The
KD of the HD37 whole mAb was 2.7×10
−9 M, which was
approximately 3-fold lower than that of the scFv fragment,
HD37-CCH (8.1×10−9 M) (not shown).
Since the presence of the His6 and c-myc tags might interfere
with the eventual clinical applications of scFv fragments, we
removed the His6 and c-myc tags from the HD37-CHC
construct, forming HD37-C (Fig. 2). The HD37-C protein had
a molecular mass of approximately 29 kDa as evident from
SDS-PAGE (Fig. 2A). Western blot analysis suggested the
presence of the variable regions in our target protein (Fig. 2B).
In addition, the His6 tag was not detected in the scFv (Fig. 2C).
A positive control, HD37-CHC, containing the His6 tag,
showed that the anti-His mAb was functioning properly.
In order to further investigate the binding activity of the
refolded HD37-C, we coupled the scFv, trace-labeled with 125I,
Fig. 3. Binding of immunoliposomes to B-lymphoid cells. 1×106 Raji cells were
incubated with the various liposome formulations at increasing PL concentra-
tions. (A) Raji cells. ■ SIL[HD37 mAb], ▴ SIL[HD37-C] and ▾ SL. (B)
Namalwa cells. ■ SIL[FMC63 mAb], ▴ SIL[HD37-C] and ▾ SL.
Fig. 4. Purification of HD37-CCH after periplasmic extraction. (A) SDS-PAGE
gel of purified HD37-CCH after purification using a Ni-NTA column. Lane M,
molecular weight markers; Lane 1, unbound fraction; Lanes 2–7, wash
fractions; lanes 8–12, eluted fractions of scFv. (B) Western blot of HD37-CCH
fragments, detected using murine anti-His mAb and then GAM-HRP. Lane M;
molecular weight markers: Lanes 1 and 2: periplasmic extracts; Lanes 3 and 4:
purified HD37-CCH; Lane 5: positive control (poly-His-containing scFv).
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Coupling densities of 19.2–25.6 μg scFv/μmol PL were
obtained (30–40% coupling efficiency), which compares
favourably with previous literature values [17]. The binding
to B-lymphoid cells in vitro was compared for SIL[HD37-C],
non-targeted liposomes (SL), and either SIL[HD37 mAb] or
SIL[FMC63 mAb] (Fig. 3A, B). SIL[HD37-C] had low
binding to CD19-positive Raji or Namalwa cells, which was
not different from control SL and was substantially lower
than the binding of liposomes targeted via the FMC63 or
HD37 mAbs.
When the HD37-CCH construct was purified from periplas-
mic extracts, modest yields of 0.4–0.6 mg/L culture were
obtained. The scFv was present in whole cell lysates and
periplasmic extracts (Fig. 4B) and was enriched in eluate
fractions after affinity purification (Fig. 4A, B). The purified
protein bound to CD19-positive cells (Fig. 1B) and was stable
in PBS. The purified HD37-CCH scFv was coupled to
liposomes at a coupling density of 14–20 μg/μmol PL (20–
29% coupling efficiency). SIL[HD37-CCH] showed increased
binding to Raji cells compared to SL (Fig. 5A, B) and the
increased binding was abolished when cells were pre-incubated
with the whole HD37 mAb in a competition experiment. Thus,
binding of SIL[HD37-CCH] was specific to CD19. In another
control, a mixture of unconjugated HD37-CCH and SL did not
result in an increase in binding compared to SL. Specific
binding of SIL[HD37-CCH] at 37 °C (permissive for
internalization) and 4 °C (non-permissive for internalization)
were also compared (Fig. 5C). Increased liposome uptake
occurred at 37 °C relative to 4 °C, probably due to recycling ofCD19 at 37 °C following receptor-mediated internalization.
When binding of SIL[HD37-CCH] to CD19-negative Molt 4
control cells was tested, there was no difference between the
binding of SIL[HD37-CCH] and SL (Fig. 5D). We also
compared the binding of SIL[HD37-CCH] and SIL[HD37
mAb] to Raji cells. Taking into consideration that each mAb has
two antigen binding sites, the number of available binding sites
on SIL[HD37-CCH] and SIL[HD37 mAb] were 0.45 nmol/
μmol PL (16 μg scFv /μmol PL) and 0.32 nmol/μmol PL (25 μg
mAb /μmol PL) respectively. At similar numbers of available
binding sites on the surfaces of liposomes, the uptake of SIL
[HD37 mAb] at 37 °C was significantly better than for the SIL
[HD37-CCH] (Fig. 5E).
In vitro MTT cytotoxicity study, with a 1 h incubation,
demonstrated that SIL-DXR[HD37-CCH] were approximately
11-fold more cytotoxic to Raji cells than untargeted SL-DXR.
The concentrations of drugs inhibiting 50% of cell growth
(IC50's) were 21±9 μM, 244±36 μM and 225±33 μM for SIL-
DXR[HD37-CCH], SL-DXR and HD37-CCH+SL-DXR,
respectively. The IC50 for the free drug was 0.7±4 μM. There
was no toxicity observed when Raji cells were treated with free
HD37-CCH at concentrations which were typically found on
the surface of SIL-DXR[HD37-CCH]. IC50's for Molt 4 cells
Fig. 5. Binding of SIL[HD37-CCH] to Raji cells. 1×106 Raji cells were incubated with increasing PL concentrations of SIL[HD37-CCH] or SL for 1 h. For the
competition study, Raji cells were pre-incubated with 100 μg of HD37 mAb (7.5- to 120-fold excess) for 15 min. Binding was measured by scintillation counting of the
liposomal 3H-CHE label. (A) Binding at 37 °C.▴ SIL[HD37-CCH],● SIL[HD37-CCH]+HD37 mAb, O HD37-CCH+SL,■ SL. (B) Binding at 4 °C.▴ SIL[HD37-
CCH],■ SL. (C) Specific binding of SIL[HD37-CCH] at 37 and 4 °C.▵ 37 °C,○ 4 °C. (D) Binding to Molt 4 cells at 37 °C.▴ SIL[HD37-CCH],■ SL. (E) Specific
binding of SIL[HD37-CCH] and SIL[HD37 mAb] at 37 °C. ▴ SIL[HD37-CCH], O SIL[HD37 mAb].
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be 136±42 μM , 106±20 μM, and 0.3±0.1 μM respectively.
4. Discussion
FMC63 and HD37 effectively bound to the B-lymphoid cell
lines, and both mAbs produced a greater than 2 log shift in
fluorescence, indicating efficient binding of the mAbs to the
CD19 antigen on intact cells. Binding profiles to Raji cells of
both antibodies were similar to those obtained with Namalwa
cells (not shown). The HD37-CCH scFv, also interacted
efficiently with Raji cells, producing approximately a 1 log
shift in fluorescence intensity. Using the standard radiolabeled
mAb assay, the reported equilibrium dissociation constant (KD)
for FMC63 mAb is 2.4×10−10 M, while the KD of HD37 mAb
is 3.3×10−9 M [44,45], which are similar to the results that we
have determined.
In this study, a very low yield of native HD37-C scFv was
obtained from the periplasmic space (∼0.1 mg/L of culture), sowe proceeded to isolate the scFv from inclusion bodies and
obtained denatured scFv in much larger quantities (∼1–2 mg/L
culture). However, this scFv required refolding. We attempted
to use a Protein L-FITC conjugate for detecting refolded HD37-
C bound to CD19 using FACS, but no binding was observed.
Therefore, we hypothesized that either the refolded HD37-C
scFv had lost its activity due to improper refolding, or the
Protein L-FITC conjugate was not able to bind to refolded
HD37-C when the scFv was bound to CD19. To further
investigate the activity of the refolded HD37-C, we conjugated
the scFv to the surface of liposomes. The refolded HD37-C,
when conjugated to liposomes, did not increase cell-binding of
these liposomes to CD19-positive Raji cells, which suggest that
the scFv fragments did not bind to CD19. Taken together, our
results seem to support our hypothesis that the refolded HD37-C
was not active.
The HD37-CCH scFv, when coupled to the surface of
liposomes, resulted in specific and increase uptake of the
immunoliposomes into Raji cells. The binding of SIL[HD37-
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liposomes. These results are similar to published studies using
the FMC63 mAb and Fab'-conjugated liposomes [16,18]. In
these studies, the conjugation of the mAb and Fab' to the
surfaces of liposomes led to internalization of the immunolipo-
somes, recycling of CD19 and higher binding/uptake at 37 °C
than at 4 °C. We had observed a significant difference in cell-
binding when SIL[HD37-CCH] was compared to SIL[HD37
mAb] at similar densities of binding sites on the surface of
liposomes. We speculate that the decrease in uptake of SIL
[HD37-CCH] is due to a decrease in affinity of the scFv for
CD19 in comparison to the mAb. Normally, a decrease in
affinity is observed when single chain fragments are compared
to their parent mAb. This agrees with our observation of
targeted liposomes where affinity of SIL[HD37-CCH] to Raji
cells was decreased by approximately 3-fold when compared to
SIL[HD37 mAb]. A decrease in avidity could also lead to the
decreased binding of SIL[HD37-CCH]. Coupling ligands with
single binding sites, e.g., Fab' or scFv, to liposomes will make
them multivalent, but the degree to which this will restore
avidity will depend on factors such as the ligand concentration
and its degree of flexibility and orientation.
The increase in cytotoxicity of SIL-DXR[HD37-CCH] can
be attributed to the targeting of the CD19 antigen and
internalization of the liposome-drug package. For a 1 h
incubation, prior to washing away the liposomes we would
expect very little leakage of DXR from either the targeted or
non-targeted formulation of liposomal DXR since they have
leakage half lives in excess of 90 h [46]. Our cytotoxicity results
with the HD37-CCH scFv fragment are consistent with our
previous results, showing that DXR-loaded anti-CD19 mAb
and Fab' immunoliposomes were more cytotoxic than SL.
[16,19,30,47]. In addition, we have shown that the increase in
cytotoxicity associated with SIL-DXR[HD37-CCH] is CD19-
mediated. The IC50's of Raji cells, treated with a mixture of
unconjugated SL-DXR+HD37-CCH and SL-DXR, and the
IC50's of Molt 4 cells (CD19-negative) treated with either SIL-
DXR[HD37-CCH] or SL-DXR, were similar.
In addition to the two constructs we have reported, we also
experimented with another anti-CD19 scFv, the n-strep-His6-
4G7-Gly4-Cys (nH-4G7-GC), kindly provided to us by Dr. G.
Fey (Friedrich-Alexander University of Erlangen-Nuremberg,
Germany). When extracted from the periplasm E. coli, the scFv
bound effectively to CD19 (not shown). Because expression in
the periplasmic space resulted in very low yields, the nH-4G7-
GC was expressed in E. coli and extracted from inclusion
bodies. However, unfolding and refolding of the scFv from
inclusion bodies did not produce sufficient quantities of
properly folded scFv for subsequent experimentation. During
the refolding procedure following extraction from inclusion
bodies, we postulate that the presence of a hydrophobic leader
sequence in the scFv led to aggregation in the isotonic buffer,
PBS.
Refolding of denatured scFv from inclusion bodies carries
the potential of increased yield. This is especially important in
the development of antibody or antibody fragments for clinical
use, since large amounts of materials will be required. Althoughthe refolding method can greatly increase production yield in
comparison to periplasmic extraction of native proteins, it may
not result in “usable” product. During the refolding process, the
scFv can be trapped in a “thermodynamic sink”, where the
protein remains in an intermediate state [48]. This thermo-
dynamic sink can lead to incomplete refolding, resulting in loss
of activity and aggregation.
Antibody-targeted liposomal drugs can selectively deliver
large payloads of drugs to cancer cells. Small antibody
fragments, such as scFv, can reduce the immunogenicity
associated with larger fragments of foreign origin. Many
groups have demonstrated the potential of using scFvs as
targeting moieties for liposomal anticancer drugs [14,17,49,50]
and at least one formulation of scFv-coupled liposomal
doxorubicin is near clinical testing [51]. In this study, we
have employed two different methods for isolating scFv
fragments from E. coli. We have found that, although isolating
scFv from inclusion bodies with subsequent refolding can
dramatically increase protein-yield, the purified scFv may not
refold properly, leading to issues with activity and stability. On
the other hand, extraction of the native scFv from the
periplasmic space, although producing relatively smaller
amounts of protein, resulted, in our hands, in proteins that
are active and are relatively stable. Therefore, we have
concluded that this is the method of choice for producing
scFv fragments for our future studies. After some preliminary
experiments with the HD37-C construct, we selected the
HD37-CCH for our subsequent experiments due to its stability
and affinity for the CD19 antigen. We have shown that, when
the scFv is conjugated to the surface of liposomes, these HD37-
CCH immunoliposomes can specifically bind to CD19-
expressing cells and trigger internalization of the liposome
package. Our initial cytotoxicity studies demonstrated that the
doxorubicin-loaded SIL[HD37-CCH] was more cytotoxic than
Caelyx®, a commercial formulation of non-targeted Stealth®
liposomal doxorubicin. Future experiments will examine the in
vivo pharmacokinetics properties and therapeutic activity of the
SIL[HD37-CCH] in comparison to liposomes targeted with the
HD37 mAb and HD37 Fab'.Acknowledgements
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